Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B

Digestive and Liver Disease

Volumn 45, Issue 7, 2013, Pages 600-605

  Bang, Sung Jo ^a   Kim, Byung Gyu ^a   Shin, Jung Woo ^a   Ju, Hyeong Uk ^a   Park, Bo Ryung ^a   Kim, Min Ho ^a   Kim, Chang Jae ^a   Park, Jae Ho ^a   Jeong, In Du ^a   Jung, Seok Won ^a   Park, Neung Hwa ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Entecavir; Partial virologic response; Primary non response

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VIROLOGY; VIRUS INHIBITION; VIRUS RESISTANCE;

EID: 84881241146     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.12.013     Document Type: Article

References (16)

1. Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503-1514.
2. Chang T.T., Lai C.L., Kew Yoon S., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:422-430.
3. Woo G., Tomlinson G., Nishikawa Y., et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010, 139:1218-1229.
4. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New England Journal of Medicine 2006, 354:1001-1010.
5. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine 2006, 354:1011-1020.
6. Chang T.T., Liaw Y.F., Wu S.S., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010, 52:886-893.
7. EASL Clinical Practice Guidelines: management of chronic hepatitis B. Journal of Hepatology 2009, 50:227-242.
8. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
9. Zoutendijk R., Reijnders J.G., Brown A., et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011, 54:443-451.
10. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology 2012, 57:167-185.
11. Ha N.B., Garcia R.T., Trinh H.N., et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Digestive Diseases and Sciences 2011, 56:2423-2431.
12. Hongthanakorn C., Chotiyaputta W., Oberhelman K., et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011, 53:1854-1863.
13. Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011, 54:91-100.
14. Kamezaki H., Kanda T., Wu S., et al. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Scandinavian Journal of Gastroenterology 2011, 46:1111-1117.
15. Chotiyaputta W., Peterson C., Ditah F.A., et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. Journal of Hepatology 2011, 54:12-18.
16. Hong S.P., Kim N.K., Hwang S.G., et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. Journal of Hepatology 2004, 40:837-844.